Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 35.8% in July

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 19,996 shares, a decline of 35.8% from the June 30th total of 31,149 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average trading volume of 85,870 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Redhill Biopharma

A hedge fund recently raised its position in Redhill Biopharma stock. Gagnon Securities LLC grew its holdings in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,102 shares of the biotechnology company’s stock after purchasing an additional 68,280 shares during the quarter. Gagnon Securities LLC owned about 1.68% of Redhill Biopharma worth $89,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Price Performance

RDHL opened at $0.65 on Friday. Redhill Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.79. The company’s 50 day moving average price is $0.82 and its two-hundred day moving average price is $0.93. The firm has a market capitalization of $3.98 million, a price-to-earnings ratio of 0.00 and a beta of 4.98.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Redhill Biopharma has a consensus rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.